CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Connect Biopharma Holdings Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.01 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $56.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.8302 (−47.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Connect Biopharma Holdings Ltd grew revenue 50.3% to $2.95M over the twelve months to Jun 30, 2026. Free cash flow was -$60.63M.
Revenue
$2.95M
+50.3% vs. a year earlier
Operating income
-$70.41M
TTM Q2 2026
Free cash flow
-$60.63M
TTM Q2 2026
EPS, diluted
-$1.19
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $56.58M
- P/E ratio
- –
- Price to sales
- 19.16
- Price to book
- 2.11
- Dividend yield
- –
- Free cash flow yield
- -107.16%
Fundamentals
- Revenue
- $2.95M
- Net income
- -$68.99M
- EPS, diluted
- -$1.19
- Free cash flow
- -$60.63M
- Book value per share
- $0.43
- Diluted shares
- 63M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$2.95M+50.3% YoY
Operating income
-$70.41M
Net income
-$68.99M
EPS, diluted
-$1.19
Free cash flow
-$60.63M
Reported periodTrailing twelve months